Last reviewed · How we verify
Remifentanil automatic — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Remifentanil automatic (Remifentanil automatic) — Centre Clinical, France.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Remifentanil automatic TARGET | Remifentanil automatic | Centre Clinical, France | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Remifentanil automatic CI watch — RSS
- Remifentanil automatic CI watch — Atom
- Remifentanil automatic CI watch — JSON
- Remifentanil automatic alone — RSS
Cite this brief
Drug Landscape (2026). Remifentanil automatic — Competitive Intelligence Brief. https://druglandscape.com/ci/remifentanil-automatic. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab